Nonalcoholic fatty liver disease: From steatosis to cirrhosis

Hepatology

Volumn 43, Issue 2 SUPPL. 1, 2006, Pages

  Farrell, Geoffrey C ^a,b   Larter, Claire Z ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CANBERRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BETAINE; CYTOKINE; GLITAZONE DERIVATIVE; METFORMIN; PENTOXIFYLLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; TROGLITAZONE; URSODEOXYCHOLIC ACID;

CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIET; DISEASE COURSE; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOGRAPHY; FIBROGENESIS; HEPATITIS; HEREDITY; HUMAN; INSULIN RESISTANCE; LIFESTYLE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER GRAFT; LIVER TOXICITY; METABOLIC SYNDROME X; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OVERNUTRITION; OXIDATIVE STRESS; PATHOGENESIS; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; STEATOSIS; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; BIOPSY; CARCINOMA, HEPATOCELLULAR; DIABETES MELLITUS; FATTY LIVER; HUMANS; INSULIN RESISTANCE; LIFE STYLE; LIVER CIRRHOSIS; LIVER DISEASES; LIVER NEOPLASMS; RISK FACTORS;

EID: 33644547706     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20973     Document Type: Review

References (157)

1. Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med 1979;67:811-816.
2. Ludwig J, Viaggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experience with an hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438.
3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;16:1221-1231.
4. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002;122:1649-1657.
5. Farrell GC. Okuda Lecture. Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region. J Gastroenterol Hepatol 2003;18:124-138.
6. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. HEPATOLOGY 2003;37:1202-1219.
7. Farrell GC, George J, dela M Hall P, McCullough AJ (eds). Fatty Liver Disease: NASH and Related Disorders. Malden, MA: Blackwell Publishing, 2005:1-319.
8. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liv Dis 2001;21:27-41.
9. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum ot clinical and pathological seventy. Gastroenterology 1999;116:1413-1419.
10. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-2474.
11. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for non-alcoholic fatty liver disease. HEPATOLOGY 2005;41:1313-1321.
12. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898-1906.
13. Mendler MH, Kanel G, Govindarajan S. Proposal for a histological scoring and grading system for non-alcoholic fatty liver disease. Liver Int 2005;25:294-304.
14. Gramlich T, Kleiner DE, McCullough AJ, Matteoni CA, Boparai N, Younossi ZM. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol 2004;35:196-199.
15. McCullough AJ. The epidemiology and risk factors of NASH. In: Farrell GC, George J, de la M Hall P, McCullough AJ, eds. Fatty Liver Disease: NASH and Related Disorders. Malden, MA: Blackwell Publishing, 2005:23-37.
16. George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998;114:311-318.
17. Bonkovsky HL, Jawaid Q, Tortorelli K, LeClair P, Cobb J, Lambrecht RW, et al. Non-alcoholic steatohepacitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999;31:421-429.
18. Norton R, Batey R, Dwyer T, MacMahon S. Alcohol consumption and the risk of alcohol related cirrhosis in women. Br Med J (Clin Res Ed) 1987;295:80-82.
19. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002-June 10-12, 2002. HEPATOLOGY 2002;36(Suppl 1):S3-S21.
20. Hayashi PH, Harrison SA, Torgerson S, Perez TA, Nochajski T, Russell M. Cognitive lifetime drinking history in nonalcoholic fatty liver disease: some cases may be alcohol related. Am J Gastroenterol 2004;99:76-81.
21. Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo M, et al. Dietary habits and their relations to insulin resistance and post-prandial lipemia in nonalcoholic steatohepatitis. HEPATOLOGY 2003;37:909-916.
22. Solga S, Alkhuraishe AR, Clark JM, Torbenson M, Greenwald A, Diehl AM, et al. Dietary composition and nonalcoholic fatty liver disease. Dig Dis Sci 2004;49:1578-1583.
23. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988;27:142-149.
24. Bellentani S, Saccoccio G, Masatti F, Croce LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000;132:112-117.
25. Hasan I, Gani RA, Machmud R, et al. Prevalence and risk factors for nonalcoholic fatty liver in Indonesia [Abstract]. J Gastroenterol Hepatol 2002;17(Suppl):S154.
26. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. HEPATOLOGY 2004;40:1387-1395.
27. Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, Iwamoto Y, et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 2005;22:1141-1145.
28. Hilden M, Christoffersen P, Juhl E, Dalgaard JB. Liver histology in a 'normal' population: examination of 503 consecutive fatal traffic casualities. Scand J Gastroenterol 1977;12:593-599.
29. Ground KE. Liver biopsy in review. Aviat Space Environ Med 1982;53:14-18.
30. Marcos A, Fisher RA, Jam JM, Olzinski AT, Shiffman ML, Sanyal AJ, et al. Selection and outcome of living donors for adult to adult right lobe transplantation. Transplantation 2000;69:2410-2415.
31. Hwang S, Lee SG, Jang SJ, Cho SH, Kim KH, Ahn CS, et al. The effect of donor weight reduction on hepatic steatosis for living donor liver transplantation. Liver Transpl 2004;10:721-727.
32. Patt CH, Yoo HY, Dibadji K, Flynn J, Thuluvath PJ. Prevalence of transaminase abnormalities in asymptomatic healthy subjects. Dig Dis Sci 2003;48:797-801.
33. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. HEPATOLOGY 1990;12:1106-1110.
34. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100.
35. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999;84:1513-1517.
36. DelGaudio A, Boschi L, DelGaudio GA, Mastrangel L, Munars D. Liver damage in obese persons. Obes Surg 2001;11:254-257.
37. Luyckx FH, Desaive C, Tiry A, Dewe W, Scheen AJ, Gielen JE, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes 1998;22:222-226.
38. Silverman EM, Sapala JA, Appelman HD. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am J Clin Pathol 1995;104:23-31.
39. Kral JG, Thung SN, Biron S, Hould FS, Lebel S, Marceau S, et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004;135:48-58, 129.
40. Roberts EA. Steatohepatitis in children. Best Pract Res Clin Gastroenterol 2002;16:749-765.
41. Manton ND, Lipsett J, Moore DJ, Davidson GP, Bourne AS, Couper RT. Non-alcoholic steatohepatitis in children and adolescents. Med J Aust 2000;173:476-479.
42. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107:1103-1109.
43. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. HEPATOLOGY 2002;35:373-379.
44. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. HEPATOLOGY 2002;35:367-372.
45. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, Steatohepatitis, and the metabolic syndrome. HEPATOLOGY 2003;37:917-923.
46. Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Maccioni D, et al. Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases. J Gastroenterol Hepatol 2003;18:1115-1117.
47. Kral JG, Schaffner F, Pierson RN Jr, Wang J. Body fat topography as an independent predictor of fatty liver. Metabolism 1993;42:548-551.
48. Omagari K, Kadokawa Y, Masuda J, Egawa I, Sawa T, Hazama H, et al. Fatty liver in non-alcoholic non-overweight Japanese adults: Incidence and clinical characteristics. J Gastroenterol Hepatol 2002;17:1089-1105.
49. Park SH, Kim BI, Kim SH, Kim HJ, Park DI, Cho YK, et al. Body fat distribution and insulin resistance: beyond obesity in nonalcoholic fatty liver disease among obese men. J Am Coll Nutr 2005 (in press).
50. Adams LA, Feldstein A, Lindor KD, Angulo P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. HEPATOLOGY 2004;39:909-914.
51. Hashimoto E, Taniai M, Kaneda H, Tokushige K, Hasegawa K, Okuda H, et al. Comparison of hepatocellular carcinoma patients with alcoholic liver disease and nonalcoholic steatohepatitis. Alcohol Clin Exp Res 2004;28:8(Suppl Proceedings):164S-168S.
52. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-121.
53. Poynard T, Ratziu V, Benhamou Y, Di Martino V, Bedossa P, Opolon P. Fibrosis in patients with chronic hepatitis C: detection and significance. Semin Liver Dis 2000;20:47-55.
54. Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003;300:1140-1142.
55. Thomas EL, Hamilton G, Patel N, O'Dwyer R, Dore CJ, Goldin RD, et al. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 2005;54:122-127.
56. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
57. Day CP, Daly AK. NASH is a genetically determined disease. In: Farrell GC, George J, de la M. Hall P, McCullough AJ, eds. Fatty Liver Disease: NASH and Related Disorders. Malden, MA: Blackwell Publishing, 2005:76-90.
58. Struben VMD, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med 2000;108:9-13.
59. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. HEPATOLOGY 1999;30;1356-1362.
60. Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003;98:2042-2047.
61. Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. HEPATOLOGY 2002;35:1485-1493.
62. Powell EE, Cooksley WGE, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. HEPATOLOGY 1990;11:74-80.
63. Caldwell SH, Hespenheide EE. Subacute liver failure in obese women. Am J Gastroenterol 2002;97:2058-2062.
64. Hui JM, Kench JG, Chitturi S, Suda A, Farrell GC, Byth K, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. HEPATOLOGY 2003;38:420-427.
65. Fassio F, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. HEPATOLOGY 2004;40:820-826.
66. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005;42:132-138.
67. Brun E, Nelson RG, Bennett PH, Imperatore G, Zoppini G, Verlato G, et al. Diabetes duration and cause-specific mortality in the Verona Diabetes Study. Diabetes Care 2000;23:1119-1123.
68. Capron J-P, Delamarre J, Dupas J-L, Braillon A, Degott C, Quenum C. Fasting in obesity: another cause of liver injury with alcoholic hyaline? Dig Dis Sci 1982;27:265-268.
69. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-140.
70. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok ASF. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. HEPATOLOGY;2002;36:1349-1354.
71. Shimada M, Hashimoto E, Taniai M, Hasegawa K, Okuda H, Hayashi N, et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2002;37:154-160.
72. Davila J, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005;54:533-539.
73. Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. HEPATOLOGY 2005;42:5-13.
74. Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology 2004;127(Suppl 1):S97-S103.
75. Adams LA, Angelo P. Recent concepts in non-alcoholic fatty liver disease. Diabetic Medicine 2005;21:1129-1133.
76. Charlton M, Kasparova P, Weston S, Lindor K, Maor-Kendler Y, Wiesner RH, et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 2001;7:608-614.
77. Bhattacharjya S, Bhattacharjya T, Quaglia A, Dhillon AP, Burroughs AK, Patch DW, et al. Liver transplantation in cirrhotic patients with small hepatocellular carcinoma: an analysis of pre-operative imaging, explant histology and prognostic histologic outcomes. Dig Surg 2004;21:152-159.
78. Ayata G, Gordon FD, Lewis WD, Pomfret E, Pomposelli JJ, Jenkins RL, et al. Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation. Hum Pathol 2002;33:1098-1104.
79. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. HEPATOLOGY 2003;37:1286-1292.
80. Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine amino-transferase, fasting insulin, and quality of life. Gut 2004;53:413-419.
81. Ioannou GN, Weiss NS, Boyko EJ, Kahn SE, Lee SP. Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. Gastroenterology 2005;128:627-635.
82. Wanless IR, Shiota K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis 2004;24:99-106.
83. Hui J, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? HEPATOLOGY 2004;40:19-22.
84. Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, De Iasio R, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to disease severity. J Clin Endocrinol Metab 2005;90:3498-3504.
85. Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, et al. Adiponectin and its receptots in non-alcoholic steatohepatitis. Gut 2005;54:117-121.
86. Diehl AM, Li ZP, Lin HZ, Yang SQ. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 2005;54:303-306.
87. Park SH, Kim BI, Yun JW, Kim JW, Park DI, Cho YK, et al. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol 2004;19:694-698.
88. Hui J, Farrell GC, Kench JG, George J. High sensitivity CRP protein values do not reliably predict the severity of histological change in NAFLD (letter). HEPATOLOGY 2004;39:1458-1459.
89. Bugianesi E, Manzini P, D'Antico S, Vanni E, Longo F, Leone N, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in non-alcoholic fatty liver. HEPATOLOGY 2004;39:179-187.
90. Younossi ZM, Gramlich T, Bacon BR, Matteoni CA, Boparai N, O'Neill R, et al. Hepatic iron and nonalcoholic fatty liver disease. HEPATOLOGY 1999;30:847-850.
91. Chitturi C, Weltman M, Farrell GC, McDonald D, Kench J, Liddle C, et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. HEPATOLOGY 2002;36:142-149.
92. Joseph AE, Saverymuttu SH, al-Sam S, Cok MG, Maxwell JD. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 1991;43:26-31.
93. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745-750.
94. Fishbein M, Castro F, Cheruku S, Jain S, Webb B, Gleason T, et al. J Clin Gastroenterol 2005;39:619-625.
95. Mottin CC, Moretto M, Padoin AV, Swarowsky AM, Toneto MG, Glock L, et al. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg 2004;14:635-637.
96. Mitchell DG. Focal manifestations of diffuse liver disease at MR imaging. Radiology 1992;185:1-11.
97. Debacre C, Rigauts H, Laukens P. Transient focal fatty liver infiltration mimicking liver metastasis. J Belge Radiol 1998;81:174-175.
98. Ataseven H, Yildirim MH, Yalniz M, Bahcecioglu IH, Celebi S, Ozercan IH. The value of ultrasonography and computerized tomograph in estimating the histopathological severity of nonalcoholic steatohepatitis. Acta Gastroenterol Belg 2005;68:221-225.
99. Szczepaniak LS, Nurunberg P, Leonard D, Browning JD, Reingold JS, Grundy S, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005;288:E462-E468.
100. Friedman LS. Controversies in liver biopsy: who, where, when, how, why? Curr Gastroenterol Rep 2004;6:30-36.
101. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol 2003;15:539-543.
102. Suzuki A, Angulo P, Lymp J, Li D, Satomura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 2005;25:779-786.
103. Sakugawa H, Nakayoshi T, Kobashigawa K, Yamashiro T, Maeshiro T, Miyagi S, et al. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2005;11:255-259.
104. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al. Serum markers detect the presence of fibrosis: a cohort study. Gastroenterology 2004;127:1704-1713.
105. Bookman I, Carney R, Hui J, Kench J, George J, Chitturi S, et al. Does serum hyaluronic acid help distinguish fibrosing steatohepatits (severe NASH) from benign forms of non-alcoholic fatty liver disease (NAFLD)? Value of the HAGL score [Abstract]. HEPATOLOGY 2005;42(Suppl):623A.
106. R): a prospective study. Gut 2005; Jul 14; PMID: 16020491. Available at: http://gut.bmjjournals.com/cgi/rapidpdf/gut.2005.069153v1.
107. Lowell BB, Shulman GG. Mitochondrial dysfunction and type 2 diabetes. Science 2005;307:384-387
108. Samuel VT, Liu Z-X, Qu X, Elder BD, Bilz S, Befroy D, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004;279:32345-32353.
109. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004;114:147-152.
110. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-1192.
111. Friedman J. Fat in all the wrong places. Nature 2002;415:268-269.
112. Kraegen EW, Clark PW, Jenkins AB, Daley EA, Chisholm DJ, Storlien LH. Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes 1991;40:1397-1403.
113. Kim JK, Fillmore JJ, Chen Y, Yu C, Moore IK, Pypaert M, et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci USA 2001;98:7522-7527.
114. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004;350:664-671.
115. Caldwell SH, Swerdlow RH, Khan EM, Iezzoni JC, Hespenheide EE, Parks JK, et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 1999;31:430-434.
116. Farrell GC. Signalling links in the liver: Knitting SOCS with fat and inflammation. J Hepatol 2005;43:193-196.
117. Weltman MD, Farrell GC, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P4502E1 is increased in patients with nonalcoholic steatohepatitis. HEPATOLOGY 1998;27:128-133.
118. Chalasani N, Gorski C, Asghar MS, Asghar A, Foresman B, Hall SD, et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. HEPATOLOGY 2003;37:544-550.
119. Leclercq IA, Farrell GC, Field J, Robertson G. Cyp2e1 and Cyp4a as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis. J Clin Invest 2000;105:1067-1075.
120. Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 2001;281:G1135-G1139.
121. Schattenberg JM, Wang Y, Singh R, Rigoli RM, Czaja MJ. Hepatic CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. J Biol Chem 2005;280:9887-9894.
122. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat Med 2005;11:183-190.
123. Charlton M, Sreekumar R, Rasmssen D, Lindor K, Nair KS. Apolipoprotein synthesis in nonalcoholic steatohepatitis. HEPATOLOGY 2002;35:898-904.
124. Masaki T, Chiba S, Tatsukawa H, Yasuda T, Noguchi H, Seike M, et al. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. HEPATOLOGY 2004;40:19-22.
125. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper CJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003;112:91-100.
126. Larter C, Farrell GC. Insulin resistance, adiponectin, cytokines in NASH: which is the best target to treat? J Hepatol 2006;44:253-261.
127. Carmiel-Haggai M, Cederbaum AI, Nieto N. A high-fat diet leads to the progression of non-alcoholic fatty liver disease in obese rats. FASEB J 2005;19:136-138.
128. Donnelly KI, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted with lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343-1351.
129. Day C, James O. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998;114:842-845.
130. Deng QG, She H, Cheng J, French S, Koop D, Xiong S, et al. Steatohepatitis induced by intragastric overfeeding in mice. HEPATOLOGY 2005;42:905-914.
131. de la Pena A, Leclercq I, Field J, George J, Jones B, Farrell G. NF-κB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology (in press).
132. Memon RA, Grunfeld C, Feingold KR. TNF-α is not the cause of fatty liver disease in obese mice. Nat Med 2001;7:2-3
133. George J, Pera N, Phung N, Leclercq I, Hou JY, Farrell GC. Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol 2003;39:756-764.
134. Feldstein AE, Papouchado BG, Angulo P, Sanderson S, Adams L, Gores GJ. Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2005;3:384-389.
135. Ip E, Farrell G, Hall P, Robertson G, Leclercq I. Administration of the potent PPARα agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. HEPATOLOGY 2004;39:1286-1296.
136. McCuskey R, Ito Y, Robertson GR, McCuskey MK, Perry M, Farrell GC. Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. HEPATOLOGY 2004;40:386-393.
137. Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression of fibrosis in nonalcoholic steatohepatitis. HEPATOLOGY 2001;34:738-744.
138. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350.
139. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
140. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990;99:1408-1413.
141. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27:103-107.
142. Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005;100:1072-1081.
143. Dixon JB, Bhathal PS, Hughs NR, O'Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. HEPATOLOGY 2004;39:1647-1654.
144. Angulo P. Management of NASH: current and future perspectives on treatment. In: Farrell GC, George J, de la M Hall P, McCullough AJ, eds. Fatty Liver Disease: NASH and Related Disorders. Malden, MA: Blackwell Publishing, 2005:194-207.
145. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. HEPATOLOGY 2004;23:1464-1467.
146. Saibara T, Onishi S, Ogawa Y, Yoshida S, Enzan H. Bezafibrate for tamoxiten-induced non-alcoholic steatohepatitis. Lancet 1999;353:1802.
147. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved non-alcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. HEPATOLOGY 2003;38:1008-1017.
148. Pomrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. HEPATOLOGY 2004;39:188-196.
149. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082-1090.
150. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, et al. Ursodeoxycholic acid for treatment of non-alcoholic steatohepatitis: results of a randomized trial. HEPATOLOGY 2004;39:770-778.
151. Lavine JE. Vitamin E treatment of non-alcoholic steatohepatitis in children: a pilot study. J Pediatr 2000;136:734-738.
152. Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004;2:1107-1115.
153. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-β1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001;15:1667-1672.
154. Harrison SA, Togerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with non-alcoholic steatohepatitis. Am J Gastroenterol 2003;98:2485-2490.
155. Miglio F, Rovati EC, Santoro A, Setkikar I. Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. Arzneimittelforschung 2000;50:722-727.
156. Abdelmalek M, Angulo P, Jorgensen RA, Sylvestre P, Lindor KD. Betaine, a promising new agent for patients with non-alcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001;96:2711-2717.
157. Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004;99:2365-2368.